| Q34623716 | Bioavailability of magnesium from different pharmaceutical formulations |
| Q34040676 | Diet and risk of kidney stones in the Oxford cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC). |
| Q58004538 | Effect of hydroalcoholic extract from Copaifera langsdorffii leaves on urolithiasis induced in rats |
| Q36761697 | Environmental factors in the pathophysiology of recurrent idiopathic calcium urolithiasis (RCU), with emphasis on nutrition |
| Q93017837 | Genome-wide Association Study of 24-Hour Urinary Excretion of Calcium, Magnesium, and Uric Acid |
| Q37579035 | Major and trace elements in lithogenesis |
| Q46800533 | Oxalate and its handling in a low stone risk vs a stone-prone population group |
| Q79488995 | Serum, urinary and stone zinc, iron, magnesium and copper levels in idiopathic calcium oxalate stone patients |
| Q43240000 | Stone composition and metabolic status |
| Q40609165 | The effect of ions at the surface of calcium oxalate monohydrate crystals on cell-crystal interactions |
| Q34380395 | Theobromine inhibits uric acid crystallization. A potential application in the treatment of uric acid nephrolithiasis |
| Q41535988 | Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation |